Publications PD Dr. med. Heinz Läubli PhD
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clin Cancer Res. 2019.
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA oncology. 2019.
Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Arch. 2019.
Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. Journal for immunotherapy of cancer. 2019.
Siglec-9 Regulates an Effector Memory CD8<sup>+</sup> T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. Cancer immunology research. 2019.
Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes With Infliximab. Diabetes Care. 2019.
Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. NAT IMMUNOL (PRINT-AUSGABE). 2019.
Cancer Immunotherapy. GLYCOBIOLOGY (PRINT-AUSGABE). 2018.
Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions. Swiss Med Wkly. 2018.
Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. Journal for immunotherapy of cancer. 2018.
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J CLIN INVEST (PRINT-AUSGABE). 2018.
Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer. Glycobiology. 2018.
The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology. 2018.
The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. CANCER IMMUNOL IMMUN (PRINT-AUSGABE). 2018.
Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab. Journal for immunotherapy of cancer. 2018.
Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. Journal for immunotherapy of cancer. 2017.
Antimetastatic Properties of Low Molecular Weight Heparin. J. Clin. Oncol.. 2016.
Sialic acids in cancer biology and immunity. Glycobiology. 2016.
A red meat-derived glycan promotes inflammation and cancer progression. Proc Natl Acad Sci U S A. 2015.
Reply to Mackenzie: A comparison of Neu5Gc and α-gal xenoantigens. Proc. Natl. Acad. Sci. U.S.A.. 2015.
Siglec receptors impact mammalian lifespan by modulating oxidative stress. eLife. 2015.
Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci U S A. 2014.
Hormesis in cancer immunology: Does the quantity of an immune reactant matter? Oncoimmunology. 2014.
Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A. 2014.
Involvement of a non-human sialic Acid in human cancer. Front Oncol. 2014.
Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. J Biol Chem. 2014.
Selectins as mediators of lung metastasis. Cancer microenvironment : official journal of the International Cancer Microenvironment Society. 2010.
Selectins promote tumor metastasis. Semin. Cancer Biol.. 2010.
Heparins attenuate cancer metastasis: are selectins the link? Cancer Invest.. 2009.
Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood. 2009.
L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest. CANCER RES (PRINT-AUSGABE). 2006.